Top

Published in:

01-05-2019 | Hepatitis B | Original Article

Chronic hepatitis B viral infection among RA patients—a cross-sectional control study

Authors: Naim Mahroum, Abdulla Watad, Shmuel Tiosano, Ashraf Hejly, Hussein Mahagna, Roy Waknin, Doron Comaneshter, Arnon D. Cohen, Howard Amital

Published in: Clinical Rheumatology | Issue 5/2019

Abstract

Background and objectives

Rheumatoid arthritis (RA) is the most common inflammatory joint disorder presenting also with extra-articular manifestations. As many other autoimmune diseases, it has been suggested that infectious diseases might contribute to its emergence. Hepatitis viruses were suggested by several reports as a trigger of RA onset. We aimed to assess the association between RA and chronic hepatitis B viral infection (HBV).

Methods

Patients with RA were compared with age- and sex-matched controls regarding the proportion of chronic HBV infection in a case-control study. The chi-square and t tests were used for univariate analysis, whereas a logistic regression model was used for multivariate analysis. The study was performed utilizing the medical database of Clalit Health Services.

Results

There was a significantly higher proportion of chronic HBV infection in RA patients compared with controls (1.19% vs 0.63%, respectively; p < 0.001). In a multivariate logistic regression analysis, RA was significantly associated with chronic HBV infection (OR = 1.89, 95%CI 1.55–2.29, p < 0.001).

Conclusions

Patients with RA have a greater proportion of chronic HBV infection than matched controls. Screening for HBV infection among RA patients may be warranted.

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219. https://doi.org/10.1056/NEJMra1004965 CrossRefPubMed

Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356–361. https://doi.org/10.1038/nature01661 CrossRef

Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62(8):722–727CrossRefPubMedPubMedCentral

Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL (2011) Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995–2007 versus 1985–1994: a population-based study. J Rheumatol 38(6):983–989CrossRefPubMedPubMedCentral

Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481–494CrossRefPubMed

Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1307CrossRefPubMed

Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(3):330–336. https://doi.org/10.1136/ard.2007.086348 CrossRefPubMed

Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68(4):460–469. https://doi.org/10.1136/ard.2008.101964 CrossRefPubMed

Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10(2):R45. https://doi.org/10.1186/ar2404 CrossRefPubMedPubMedCentral

10.

van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4(2):87–93. https://doi.org/10.1186/ar395 CrossRefPubMed

11.

Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheumatol 46(9):2287–2293CrossRef

12.

Baum J (1971) Infection in rheumatoid arthritis. Arthritis Rheumatol 14(1):135–137CrossRef

13.

Gendelman O, Mahroum N, Comaneshter D, Rotman-Pikielny P, Cohen AD, Amital H, Sherf M (2017) Hepatitis B carrier state among SLE patients: case-control study. Immunol Res 65(1):257–261. https://doi.org/10.1007/s12026-016-8834-6 CrossRefPubMed

14.

Maya R, Gershwin ME, Shoenfeld Y (2008) Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 34(1):85–102CrossRefPubMed

15.

Watad A, Azrielant S, Bragazzi NL, Sharif K, David P, Katz I, Aljadeff G, Quaresma M, Tanay G, Adawi M, Amital H, Shoenfeld Y (2017) Seasonality and autoimmune diseases: the contribution of the four seasons to the mosaic of autoimmunity. J Autoimmun 82:13–30. https://doi.org/10.1016/j.jaut.2017.06.001 CrossRefPubMed

16.

Mahroum N, Hejly A, Tiosano S, Gendelman O, Comaneshter D, Cohen AD, Amital H (2017) Chronic hepatitis C viral infection among SLE patients: the significance of coexistence. Immunol Res 65(2):477–481. https://doi.org/10.1007/s12026-016-8886-7 CrossRefPubMed

17.

Ramos-Casals M, Muñoz S, Medina F, Jara L-J, Rosas J, Calvo-Alen J, Brito-Zerón P, Forns X, Sánchez-Tapias J-M (2009) Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36(7):1442–1448CrossRefPubMed

18.

De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M, Martellucci S, de Vincentiis M (2016) Polyarteritis nodosa: a contemporary overview. Autoimmun Rev 15(6):564–570CrossRefPubMed

19.

Chen YL, Jing J, Mo YQ, Ma JD, Yang LJ, Chen LF, Zhang X, Yan T, Zheng DH, Pessler F, Dai L (2018) Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis. Arthritis Res Ther 20(1):130. https://doi.org/10.1186/s13075-018-1623-y CrossRefPubMedPubMedCentral

20.

Hsu CS, Lang HC, Huang KY, Lin HH, Chen CL (2016) Association of rheumatoid arthritis and hepatitis B infection: a nationwide nested case-control study from 1999 to 2009 in Taiwan. Medicine (Baltimore) 95(18):e3551CrossRef

21.

World Health Organization (2017) Global Hepatitis Programme. Global hepatitis report, 2017

22.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625–639CrossRef

23.

Kanduc D, Shoenfeld Y (2016) From HBV to HPV: designing vaccines for extensive and intensive vaccination campaigns worldwide. Autoimmun Rev 15(11):1054–1061. https://doi.org/10.1016/j.autrev.2016.07.030 CrossRefPubMed

24.

Watad A, Bragazzi NL, Adawi M, Aljadeff G, Amital H, Comaneshter D, Cohen AD, Amital D (2017) Anxiety disorder among rheumatoid arthritis patients: insights from real-life data. J Affect Disord 213:30–34. https://doi.org/10.1016/j.jad.2017.02.007 CrossRefPubMed

25.

Watad A, Bragazzi NL, Tiosano S, Yavne Y, Comaneshter D, Cohen AD, Amital H (2018) Alzheimer’s disease in systemic sclerosis patients: a nationwide population-based cohort study. J Alzheimers Dis 65(1):117–124CrossRefPubMed

26.

Watad A, Tiosano S, Azrielant S, Whitby A, Comaneshter D, Cohen AD, Shoenfeld Y, Amital H (2017) Low levels of calcium or vitamin D - which is more important in systemic lupus erythematosus patients? An extensive data analysis. Clin Exp Rheumatol 35(1):108–112PubMed

27.

Watad A, Tiosano S, Yahav D, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (2017) Behcet’s disease and familial Mediterranean fever: two sides of the same coin or just an association? A cross-sectional study. Eur J Intern Med 39:75–78. https://doi.org/10.1016/j.ejim.2016.10.011 CrossRefPubMed

28.

Dvir R, Sautto GA, Mancini N, Racca S, Diotti RA, Clementi M, Memoli M (2017) Autoimmune hepatitis and occult HCV infection: a prospective single-centre clinical study. Autoimmun Rev 16(3):323–325. https://doi.org/10.1016/j.autrev.2017.01.015 CrossRefPubMed

29.

Tosato G, Steinberg AD, Blaese RM (1981) Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 305(21):1238–1243CrossRefPubMed

30.

Wilder RL, Crofford LJ (1991) Do infectious agents cause rheumatoid arthritis? Clin Orthop Relat Res (265):36–41

31.

Balandraud N, Roudier J (2018) Epstein-Barr virus and rheumatoid arthritis. Joint Bone Spine 85(2):165–170. https://doi.org/10.1016/j.jbspin.2017.04.011 CrossRefPubMed

32.

Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52(1):53–61CrossRefPubMed

33.

Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258–265. https://doi.org/10.1016/s0140-6736(14)61704-9 CrossRefPubMedPubMedCentral

34.

Alpert E, Isselbacher KJ, Schur PH (1971) The pathogenesis of arthritis associated with viral hepatitis: complement-component studies. N Engl J Med 285(4):185–189CrossRefPubMed

35.

Dienstag JL (1981) Hepatitis B as an immune complex disease. Semin Liver Dis 1(1):45–57. https://doi.org/10.1055/s-2008-1063929 CrossRefPubMed

36.

Cacoub P, Saadoun D, Bourlière M, Khiri H, Martineau A, Benhamou Y, Varastet M, Pol S, Thibault V, Rotily M (2005) Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 43(5):764–770CrossRefPubMed

37.

Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH (2018) Practice pattern of hepatitis B testing in rheumatoid arthritis patients: a cross-national comparison between the US and Taiwan. Arthritis Care Res (Hoboken) 70(1):30–38. https://doi.org/10.1002/acr.23241 CrossRef

38.

Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21(1):16–23CrossRefPubMed

39.

Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46(4):556–564CrossRefPubMed

40.

Lahiri M, Dixon WG (2015) Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 29(2):290–305CrossRefPubMed

41.

Jeong H, Baek SY, Kim SW, Eun YH, Kim IY, Kim H, Lee J, Koh E-M, Cha H-S (2017) Comorbidities of rheumatoid arthritis: results from the Korean National Health and Nutrition Examination Survey. PLoS One 12(4):e0176260CrossRefPubMedPubMedCentral

Title: Chronic hepatitis B viral infection among RA patients—a cross-sectional control study
Authors: Naim Mahroum
Abdulla Watad
Shmuel Tiosano
Ashraf Hejly
Hussein Mahagna
Roy Waknin
Doron Comaneshter
Arnon D. Cohen
Howard Amital
Publication date: 01-05-2019
Publisher: Springer London
Keywords: Hepatitis B
Rheumatoid Arthritis
Published in: Clinical Rheumatology / Issue 5/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04448-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study

Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients

Correction to: Risk of adverse outcomes in patients with rheumatoid arthritis hospitalized for stroke—a cross-sectional study

PANLAR consensus statement on biosimilars

Plasma let-7i, miR-16, and miR-221 levels as candidate biomarkers for the assessment of ankylosing spondylitis in Mexican patients naïve to anti-TNF therapy

Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials